Chemomab Therapeutics Ltd
CMMB1.015USD
-0.010-0.98%
Market hours （ET）Quotes delayed by 15 min
19.15MMarket Cap
LossP/E TTM
More Details of Chemomab Therapeutics Ltd Company
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Company Info
Ticker SymbolCMMB
Company nameChemomab Therapeutics Ltd
IPO dateAug 14, 2012
CEODr. Adi Mor, Ph.D.
Number of employees16
Security typeDepository Receipt
Fiscal year-endAug 14
AddressKiryat Atidim, Building 7
CityTEL AVIV-YAFO
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code6158002
Phone972773310156
Websitehttps://www.chemomab.com/
Ticker SymbolCMMB
IPO dateAug 14, 2012
CEODr. Adi Mor, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 19
Updated: Sat, Jul 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Shareholders
Shareholders
Proportion
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.48%
Hedge Fund
5.93%
Family Office
5.91%
Corporation
5.78%
Investment Advisor
3.31%
Research Firm
0.83%
Private Equity
0.69%
Investment Advisor/Hedge Fund
0.20%
Venture Capital
0.07%
Other
67.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
36
5.04M
26.29%
-1.09M
2025Q1
38
6.66M
34.89%
+231.83K
2024Q4
41
7.89M
41.83%
+519.06K
2024Q3
37
7.12M
38.75%
+430.17K
2024Q2
36
5.24M
33.24%
-261.90K
2024Q1
39
5.24M
33.39%
-405.62K
2023Q4
41
5.39M
34.50%
+2.72K
2023Q3
43
5.63M
49.23%
-777.20K
2023Q2
42
5.63M
49.23%
-912.41K
2023Q1
44
6.00M
54.09%
-854.86K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Otto (Erik)
1.16M
6.03%
+1.16M
--
Nov 21, 2024
Apeiron Investment Group Ltd
1.13M
5.91%
+404.86K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
1.11M
5.78%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
900.43K
4.7%
-314.15K
-25.86%
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
578.29K
3.02%
-165.84K
-22.29%
Mar 31, 2025
Mor George (Adi)
317.07K
1.65%
--
--
Dec 31, 2024
Ikarian Capital LLC
213.05K
1.11%
--
--
Mar 31, 2025
George (Kobi)
200.24K
1.04%
-50.91K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
141.22K
0.74%
-10.00K
-6.61%
Dec 31, 2024
OrbiMed Advisors, LLC
131.27K
0.69%
-1.61M
-92.46%
Jun 23, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Date
Type
Ratio
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
